Image

Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock

Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock

Recruiting
40 years and older
All
Phase N/A

Powered by AI

Overview

Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP (mean arterial blood pressure) targets during vasopressor therapy for shock in ICU are individualized based on patients' own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings.

Hypothesis We hypothesize that targeting a patient's pre-illness MAP during management of shock can minimize the degree of MAP-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU.

Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality.

Significance To date no major RCT has tested this strategy among ICU patients with shock. This pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care.

Eligibility

Inclusion Criteria:

  • ICU patients aged greater than or equal to 40 years
  • The patient is deemed to be in shock, defined as clinician-initiated vasopressor/inotropic therapy AND supported by any of the following within the last 24
    hours
    • Lactate level greater than or equal to 2 mmol/l or base deficit greater than or equal to 3 mmol/l,
    • Urine output less than or equal to 0.5 ml/kg/h or <40 ml/h for 2 or more consecutive hours
    • Respiratory rate >22 per minute
    • Altered mentation (Glasgow Coma Score <14)

Exclusion Criteria:

  • Patients who are moribund, or have documented not-for-resuscitation orders
  • At least 24 hours have lapsed from the time of initiation of vasopressor or inotropic support
  • Patients who are either receiving or are deemed to imminently need renal replacement therapy.
  • Patients who already have an increase in serum creatinine of >350 µmol/l from baseline.
  • End stage renal disease
  • Patients where trauma is the main reason for the current ICU admission.
  • Previously enrolled in the REACT Shock RCT
  • Pregnancy, if known
  • Active bleeding (clinical suspicion or >2 packed red blood cells within last 24 hours)
  • Insufficient (less than two) pre-illness BP readings are available.
  • Patients on extracorporeal support (such as extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist device).
  • Potential contraindications to either higher or lower BP targets (including but not limited to)
    • Cerebral perfusion pressure guided therapy e.g. intracranial hemorrhage or subarachnoid hemorrhage or traumatic brain injury
    • Abdominal perfusion pressure guided therapy
    • Aortic injury (e.g. dissection or post-operative)
    • Post cardiac surgery
    • Any other condition requiring higher or lower BP target specifically

Study details
    Critical Illness
    Shock

NCT05850962

Rakshit Panwar

17 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.